R3 Funding & Investors
R3 Vascular creates bioresorbable scaffold technology with a sirolimus coating for the treatment of peripheral arterial disease. R3 Vascular's polymer and proprietary technologies are used to create scaffolds that balance strength and flexibility for the treatment of peripheral arterial disease. The magnitude BRS device is the thinnest BRS ever tested in this clinical setting, with a strut thickness of 98 microns across its entire usable range of diameters.
r3vascular.comTotal Amount Raised: $104,800,000
R3 Funding Rounds
Series B
$87,000,000
Series B Investors
Deerfield Management415 CapitalSeries A
$17,800,000
Series A Investors
415 Capital
Funding info provided by Diffbot.